MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

CureVac NV

Fermé

5.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.41

Max

5.43

Chiffres clés

By Trading Economics

Revenu

-8.3M

-60M

Ventes

352K

1.2M

P/E

Moyenne du Secteur

5.356

37.257

Marge bénéficiaire

-4,816.546

Employés

825

EBITDA

-8.2M

-55M

Dividendes

By Dow Jones

Prochains Résultats

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.4M

1.2B

Ouverture précédente

5.42

Clôture précédente

5.42

Score Technique

By Trading Central

Confiance

Bullish Evidence

CureVac NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 juin 2025, 14:20 UTC

Acquisitions, Fusions, Rachats

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 juin 2025, 13:34 UTC

Actions en Tendance

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Comparaison

Variation de prix

CureVac NV prévision

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

3.47 / 3.755Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
help-icon Live chat